webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Mc-Leu-Gly-Arg

  CAS No.:   Cat No.: BADC-01281   Purity: ≥95% 4.5  

Mc-Leu-Gly-Arg is a protease-sensitive peptide ADC linker designed for tumor-selective drug release, improving antibody-drug conjugate efficacy and reducing systemic side effects in targeted cancer therapy.

Mc-Leu-Gly-Arg

Structure of

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C21H34N6O6
Molecular Weight
466.53
Shipping
Room temperature
Shipping
-20°C

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Solubility
10 mm in DMSO
Shelf Life
0-4°C for short term (days to weeks), or -20°C for long term (months).
Shipping
Room temperature
Storage
-20°C

Mc-Leu-Gly-Arg, a peptide composed of leucine, glycine, and arginine, is a versatile compound with various applications in biochemistry, pharmacology, and biotechnology. Its unique sequence, featuring hydrophobic and positively charged amino acids, makes it particularly useful in peptide synthesis, drug development, and therapeutic research. The structure and properties of this peptide facilitate its use in targeting specific biological processes and improving the efficacy of pharmaceutical agents.

One significant application of Mc-Leu-Gly-Arg is in the field of drug delivery systems, particularly in the development of targeted therapies. The arginine residue, with its positive charge, interacts favorably with negatively charged cellular membranes or specific receptors, enabling the peptide to cross cell barriers more efficiently. This property is especially valuable in the design of peptide-based drugs that require precise targeting to specific cells or tissues, such as cancer cells or inflamed tissues. By modifying Mc-Leu-Gly-Arg, researchers can enhance the delivery of therapeutic agents directly to the desired site of action, increasing treatment efficacy and minimizing side effects.

Another key application of Mc-Leu-Gly-Arg is in the study of immune system modulation. The presence of arginine in the sequence can influence nitric oxide (NO) production, a critical signaling molecule involved in immune response and vascular function. Researchers use Mc-Leu-Gly-Arg to study its effects on immune cell activation, particularly in relation to cytokine production and macrophage function. This peptide has potential applications in immunotherapy, where it can be used to modulate immune responses to combat infections, inflammation, or even cancer.

Mc-Leu-Gly-Arg is also utilized in protein-protein interaction studies, particularly in the exploration of peptide-based inhibitors or activators. The leucine and arginine residues contribute to the peptide’s ability to mimic natural substrates or binding partners in biological systems. By studying Mc-Leu-Gly-Arg, researchers can identify new targets for drug development or gain insights into the molecular mechanisms governing critical cellular functions. This application is crucial in the development of small molecule inhibitors for diseases such as cancer, autoimmune disorders, and cardiovascular diseases.

Furthermore, Mc-Leu-Gly-Arg has important applications in biomaterials and tissue engineering. The sequence’s amphipathic nature, with hydrophobic leucine and hydrophilic glycine and arginine, allows it to interact with both aqueous environments and lipid membranes. This property is exploited in the design of biomaterials for scaffolds or coatings in regenerative medicine. These materials promote cell adhesion, proliferation, and differentiation, which are essential for tissue repair and regeneration. Mc-Leu-Gly-Arg can also be incorporated into drug delivery carriers, improving biocompatibility and ensuring controlled release of therapeutic agents.

Finally, Mc-Leu-Gly-Arg plays a role in diagnostics, particularly in the design of biosensors and molecular imaging probes. Its ability to bind to specific cellular targets makes it useful in the development of peptide-based probes for imaging or diagnostic applications. By attaching Mc-Leu-Gly-Arg to imaging agents, researchers can track peptide distribution within the body, providing valuable information for disease detection and monitoring treatment progress.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Acetylene-linker-Val-Cit-PABC-MMAE | 2,5-Dioxopyrrolidin-1-yl 3-Hydroxypropanoate | OSu-Glu-vc-PAB-MMAE | DBCO-PEG3 acetic-EVCit-PAB | Propargyl-PEG4-NHS ester | THP-SS-alcohol | Bis-PEG4-NHS ester | BCN-PEG4-NHS ester | 4-Formyl-N-(2-(3-isopropylphenoxy)ethyl)benzamide | N-Hydroxysuccinimidyl-4-azidobenzoate | Mc-Leu-Gly-Arg
Send Inquiry
Verification code
Inquiry Basket